



# ALL ABOUT



medanta

THE MEDICITY

**SECTOR - HEALTHCARE**



**Issue Opens - NOVEMBER 3 - NOVEMBER 7**

**Price Band**

**₹350 to ₹368**

**Face Value**

**₹2**

**Lot Size**

**44 SHARES**

**Issue Size**

**₹2205 CR**

**Issue Type**

**BOOK BUILT**

**RESEARCH@GANESHSTOCK.COM**



# Important Events

**Issue Size**

**INR2205.57 Cr**

**Fresh Issue**

**INR500.00 Cr {14880952 Shares}**

**Offer for Sale**

**INR1705.57 Cr {50,761,000 Shares}**

**Basis of Allotment**

**Nov 11, 2022**

**Initiation of Refunds**

**Nov 14, 2022**

**Credit of Shares to  
Demat**

**Nov 15, 2022**

**DCX Systems IPO**

**Nov 16, 2022**

**Listing Date**

## Promoters

- **DR. NARESH TREHAN (CHAIRMAN & MANAGING DIRECTOR)**
- **SUNIL SACHDEVA (NON-EXECUTIVE DIRECTOR)**
- **VIKRAM SINGH MEHTA (NON-EXECUTIVE INDEPENDENT DIRECTOR)**

**Promoters collectively hold 35% of the Equity Share .**





# ABOUT COMPANY

- **Global Health, founded by Naresh Trehan, a renowned thoracic and cardiovascular surgeon, is one of the leading multi-specialty private tertiary care providers in the Northern region. and east of India. It is a leading private healthcare provider committed to its core mission of providing affordable, world-class healthcare services to supported patients. aid. through technology and research.**
- **Dr. Dr. Trehan has been conferred the prestigious Padma Bhushan and Padma Shri, the third and fourth highest civilian honors in India, and the BC Roy Award, in recognition of his outstanding contributions to medicine.**
- **Under the brand name “Medanta”, the company has a network of four operating hospitals in Gurugram, Indore, Ranchi and Lucknow, one under construction with an operating outpatient department in Patna and one in Noida under construction. during development planning.**





# PRODUCT PORTFOLIO

## key specialties of Medanta

- cardiology and cardiac science,
- neurosciences,
- oncology,
- digestive and hepatobiliary sciences,
- orthopaedics,
- liver transplant, and kidney and urology.

## OBJECTS OF THE OFFER

**THE NET PROCEEDS FROM THE ISSUE ARE PROPOSED TO BE UTILIZED BY THE COMPANY FOR THE FOLLOWING OBJECTS:**

- 1. REPAYMENT/PREPAYMENT OF BORROWINGS, IN FULL OR PART, OF OUR SUBSIDIARIES, GHPPL AND MHPL; AND**
- 2. GENERAL CORPORATE PURPOSES**



# TRACK RECORD OF FINANCIAL PERFORMANCE

- REVENUE FROM OPERATIONS FOR FISCAL 2019, 2020 AND 2021 WAS ₹ 1500CR, ₹1446CR AND ₹2166CR, RESPECTIVELY. THE GROWTH IN THE REVENUE FROM OPERATIONS INCREASED WITH CAGR OF 20%.
- EBITDA WAS ₹230CR, ₹222CR AND ₹ 489CR FOR THE FINANCIAL YEARS ENDED, 2020 , 2021, & 2022 RESPECTIVELY
- PAT WAS ₹ 36.3CR, ₹28.81CR AND ₹196CR FOR THE FINANCIAL YEARS ENDED 2020 , 2021 & 2022 RESPECTIVELY
- GLOBAL HEALTH LTD HAS POSTED TOTAL ASSETS OF RS. 2666CR. , RS. 2694.1AND RS.3145 FY22. FOR FOR THE FINANCIAL YEARS ENDED, 2020 , 2021 & 2022 RESPECTIVELY.
- Total Liabilities 621.94 in FY 20 644.1 in FY21 and 837 for FY22
- GLOBAL HEALTH LTD HAS REPORTED AN EPS OF RS. 1.45 , RS. 1.15 & RS, 7.78 FOR THE FY20, 21 & 22 AND AN AVERAGE RONW OF 5.53 %.
- NET CASH REPORTED FOR THE YEARS 604.54 IN FY20 1475.71 IN FY21 & 694.66 IN FY 22





# STRENGTHS

- **Doctor-led' hospitals driven by skilled and experienced doctors who are among the best in the healthcare space.**
- **Top tier 3 and 4 healthcare providers of India is recognized for its clinical expertise especially in the treatment of complex cases.**
- **Large-scale hospitals with world-class infrastructure and advanced medical equipment and technology.**
- **Focus on underserved areas with high population density and presence in major city or state capital (NCR, Lucknow and Patna)**
- **Opportunities to grow in existing facilities and diversify into new services, including digital health.**

# RISKS

- **Inability to pass on high costs such as labor costs, infrastructure maintenance and repair costs, and high medical equipment costs to patients.**
- **Strict restrictions to slow the spread of Covid-19, including restrictions on international and local travel.**
- **Certain land parcels on which the hospital buildings and clinics operate are neither owned by us nor leased to us on a perpetual basis.**
- **Facilities that are under development or to be developed may experience construction delays before full operational capacity is reached.**



